A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon

References

• Incidence rates by site.MOPH; 2016. https://www.moph.gov.lb/en/Pages/8/19526/national-cancer-registry. Accessed November 29, 2021.
   Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi:10.1002/cncr.24760
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–1676. doi:10.1200/JCO.2006.09.0928
   PubMed Web of Science ®Google Scholar
• Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103(1):21–30. doi:10.1093/jnci/djq456
   PubMedGoogle Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947. doi:10.1200/JCO.2000.18.16.2938
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23(36):9441–9442. doi:10.1200/JCO.2005.04.4792
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136–147. doi:10.1200/JCO.2000.18.1.136
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047. doi:10.1016/S0140-6736(00)02034-1
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–914. doi:10.1056/NEJM200009283431302
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60–65. doi:10.1200/JCO.2003.10.066
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J Clin Oncol. 2005;23(16):3697–3705. doi:10.1200/JCO.2005.05.112
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. doi:10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–2019. doi:10.1200/JCO.2007.14.9930
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544. doi:10.1200/JCO.2006.09.6305
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842–1847. doi:10.1093/annonc/mdp233
   PubMed Web of Science ®Google Scholar
• Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–870. doi:10.1634/theoncologist.2009-0071
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Bekaii-Saab TS, Bendell JC, et al. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol. 2014;26(6):323–332. doi:10.1016/j.clon.2014.03.001
   PubMed Web of Science ®Google Scholar
• Khakoo S, Chau I, Pedley I, et al. ACORN: observational study of bevacizumab in combination with first-line chemotherapy for treatment of metastatic colorectal cancer in the UK. Clin Colorectal Cancer. 2019;18(4):280–291.e285. doi:10.1016/j.clcc.2019.07.003
   PubMed Web of Science ®Google Scholar
• Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol. 2015;26(6):1201–1207. doi:10.1093/annonc/mdv130
   PubMed Web of Science ®Google Scholar
• Stein A, Petersen V, Schulze M, et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. Acta Oncol. 2015;54(2):171–178. doi:10.3109/0284186X.2014.961649
   PubMed Web of Science ®Google Scholar